Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Pfizer’s CD22-targeted cancer drug inotuzumab wins an accelerated OK at FDA
Pfizer’s CD22-targeted cancer drug inotuzumab wins an accelerated OK at FDA
Pfizer’s CD22-targeted cancer drug inotuzumab wins an accelerated OK at FDA
Submitted by
admin
on August 17, 2017 - 11:52pm
Source:
Endpoints
News Tags:
Pfizer
inotuzumab ozogamicin
acute lymphoblastic leukemia
Headline:
Pfizer’s CD22-targeted cancer drug inotuzumab wins an accelerated OK at FDA
Do Not Allow Advertisers to Use My Personal information
